Literature DB >> 22534500

Adherence styles of schizophrenia patients identified by a latent class analysis of the Medication Adherence Rating Scale (MARS): a six-month follow-up study.

Susanne Jaeger1, Carmen Pfiffner, Prisca Weiser, Reinhold Kilian, Thomas Becker, Gerhard Längle, Gerhard Wilhelm Eschweiler, Daniela Croissant, Wiltrud Schepp, Tilman Steinert.   

Abstract

The purpose of this study was to examine patients' response profiles to the Medication Adherence Rating Scale (MARS) and to evaluate the potential of response styles as predictors of the future course of psychotic disorders in terms of rehospitalisation and maintenance of medication. A total of 371 psychiatric in-patients with schizophrenia or schizoaffective disorder who were taking part in a naturalistic long-term study completed a German version of the MARS. A Latent Class Analysis (LCA) was performed. Five latent classes of response styles could be identified: "moderately adherent", "critical discontinuers", "good compliers", "careless and forgetful", and "compliant sceptics". Class membership was found to be related to the severity of symptoms, level of functioning, insight into illness, insight into necessity of treatment, treatment satisfaction and medication side effects. At a six-month follow-up appointment, significant differences between the classes persisted. Participants showing a "good compliers" response pattern had a significantly better prognosis in terms of rehospitalisation rate and maintenance of the original medication than "critical discontinuers". Evaluation of the MARS by studying response profiles provides informative results that reach beyond the results obtained by an evaluation by scores. Patients can be classified into adherence groups that are of predictive value for long-term patient outcome.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22534500     DOI: 10.1016/j.psychres.2012.03.033

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  8 in total

1.  Identifying targets for cardiovascular medication adherence interventions through latent class analysis.

Authors:  Talea Cornelius; Corrine I Voils; Jeffrey L Birk; Emily K Romero; Donald E Edmondson; Ian M Kronish
Journal:  Health Psychol       Date:  2018-09-10       Impact factor: 4.267

2.  Treatment selection using prototyping in latent-space with application to depression treatment.

Authors:  Akiva Kleinerman; Ariel Rosenfeld; David Benrimoh; Robert Fratila; Caitrin Armstrong; Joseph Mehltretter; Eliyahu Shneider; Amit Yaniv-Rosenfeld; Jordan Karp; Charles F Reynolds; Gustavo Turecki; Adam Kapelner
Journal:  PLoS One       Date:  2021-11-12       Impact factor: 3.240

3.  Modeling determinants of medication attitudes and poor adherence in early nonaffective psychosis: implications for intervention.

Authors:  Richard J Drake; Merete Nordentoft; Gillian Haddock; Celso Arango; W Wolfgang Fleischhacker; Birte Glenthøj; Marion Leboyer; Stefan Leucht; Markus Leweke; Phillip McGuire; Andreas Meyer-Lindenberg; Dan Rujescu; Iris E Sommer; René S Kahn; Shon W Lewis
Journal:  Schizophr Bull       Date:  2015-03-05       Impact factor: 9.306

4.  Long-term effects of involuntary hospitalization on medication adherence, treatment engagement and perception of coercion.

Authors:  Susanne Jaeger; Carmen Pfiffner; Prisca Weiser; Gerhard Längle; Daniela Croissant; Wiltrud Schepp; Reinhold Kilian; Thomas Becker; Gerhard Eschweiler; Tilman Steinert
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2013-04-19       Impact factor: 4.328

5.  A personalized BEST: characterization of latent clinical classes of nonischemic heart failure that predict outcomes and response to bucindolol.

Authors:  David P Kao; Brandie D Wagner; Alastair D Robertson; Michael R Bristow; Brian D Lowes
Journal:  PLoS One       Date:  2012-11-07       Impact factor: 3.240

6.  Effects of motivational interviewing-based adherence therapy for schizophrenia spectrum disorders: a randomized controlled trial.

Authors:  Wai Tong Chien; Jolene H C Mui; Eric F C Cheung; Richard Gray
Journal:  Trials       Date:  2015-06-14       Impact factor: 2.279

Review 7.  Medication nonadherence and psychiatry.

Authors:  Sarah C E Chapman; Rob Horne
Journal:  Curr Opin Psychiatry       Date:  2013-09       Impact factor: 4.741

Review 8.  Review of depot aripiprazole for schizophrenia.

Authors:  Farha Bilal Motiwala; Kim Stasia Siscoe; Rif S El-Mallakh
Journal:  Patient Prefer Adherence       Date:  2013-11-13       Impact factor: 2.711

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.